Therapeutic options to target the tumor stroma are limited with the most exploited exception being bevacizumab (Avastin, Roche), a monoclonal antibody that targets vascular endothelial growth factor (VEGF) and inhibits tumor angiogenesis [21]. This evidence concerns the gene VEGFA and neoplasm.